Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLU-945 in EGFR-mutant non-small cell lung cancer with acquired resistance
NL-OMON52248Phase 2Active, not recruiting
- Sponsor
- Blueprint Medicines
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tigozertinib in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Blueprint Medicines. Primary endpoints: Maximum tolerated dose, Recommended Phase 2 dose and 2 more. Started Mar 2022; status: active, not recruiting.
02
Drugs
tigozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52248.